Subscribe To
FATE / Fate Therapeutics to Present at Upcoming March Investor Conferences
Content Topics
Shenzhen
Fortune
Trend
Technology
Co
Ltd
688318
Ss
Therapeutics
Present
Upcoming
Investor
Conferences
Stock
FATE
FATE News
By GlobeNewsWire
October 25, 2023
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage more_horizontal
By Zacks Investment Research
September 7, 2023
Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? more_horizontal
By GlobeNewsWire
August 31, 2023
Fate Therapeutics to Present at Upcoming September Investor Conferences
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage b more_horizontal
By Zacks Investment Research
August 8, 2023
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to lo more_horizontal
By The Motley Fool
June 16, 2023
Why Shares of Fate Therapeutics Soared This Week
Fate Therapeutics is a clinical-stage biotech. The company focuses on cell-derived oncology and immunology therapies. more_horizontal
By Seeking Alpha
May 23, 2023
Fate Therapeutics: The Future Remains Cloudy
Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by more_horizontal
By Zacks Investment Research
May 3, 2023
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to lo more_horizontal
By Zacks Investment Research
May 3, 2023
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might dr more_horizontal